231 related articles for article (PubMed ID: 12210069)
1. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
Pelosi G; Pasini F; Olsen Stenholm C; Pastorino U; Maisonneuve P; Sonzogni A; Maffini F; Pruneri G; Fraggetta F; Cavallon A; Roz E; Iannucci A; Bresaola E; Viale G
J Pathol; 2002 Sep; 198(1):100-9. PubMed ID: 12210069
[TBL] [Abstract][Full Text] [Related]
2. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma.
Lo Muzio L; Santarelli A; Caltabiano R; Rubini C; Pieramici T; Trevisiol L; Carinci F; Leonardi R; De Lillo A; Lanzafame S; Bufo P; Piattelli A
Hum Pathol; 2005 Feb; 36(2):187-94. PubMed ID: 15754296
[TBL] [Abstract][Full Text] [Related]
3. The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.
Uke M; Rekhi B; Ajit D; Jambhekar NA
Cytopathology; 2010 Feb; 21(1):56-63. PubMed ID: 19744186
[TBL] [Abstract][Full Text] [Related]
4. p63 immunostaining in destained bronchoscopic cytological specimens.
Shtilbans V; Szporn AH; Wu M; Burstein DE
Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
7. Expression profiles of p63, p53, survivin, and hTERT in skin tumors.
Park HR; Min SK; Cho HD; Kim KH; Shin HS; Park YE
J Cutan Pathol; 2004 Sep; 31(8):544-9. PubMed ID: 15268709
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas.
Owens SR; Greenson JK
Am J Surg Pathol; 2007 Feb; 31(2):285-90. PubMed ID: 17255774
[TBL] [Abstract][Full Text] [Related]
10. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
Kaufmann O; Fietze E; Mengs J; Dietel M
Am J Clin Pathol; 2001 Dec; 116(6):823-30. PubMed ID: 11764070
[TBL] [Abstract][Full Text] [Related]
11. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
12. Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers.
Boldrup L; Coates PJ; Hedberg Y; Sjöström B; Dahlqvist A; Nylander K
Int J Oncol; 2005 Dec; 27(6):1661-7. PubMed ID: 16273222
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitous p63 expression in human esophageal squamous cell carcinoma.
Hara T; Kijima H; Yamamoto S; Kenmochi T; Kise Y; Tanaka H; Chino O; Shimada H; Takazawa K; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2004 Aug; 14(2):169-73. PubMed ID: 15254760
[TBL] [Abstract][Full Text] [Related]
15. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis.
Chen Y; Knösel T; Kristiansen G; Pietas A; Garber ME; Matsuhashi S; Ozaki I; Petersen I
J Pathol; 2003 Aug; 200(5):640-6. PubMed ID: 12898601
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
[TBL] [Abstract][Full Text] [Related]
17. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas.
Edwards PC; Bhuiya T; Kelsch RD
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 May; 97(5):613-9. PubMed ID: 15153875
[TBL] [Abstract][Full Text] [Related]
18. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.
Wang BY; Gil J; Kaufman D; Gan L; Kohtz DS; Burstein DE
Hum Pathol; 2002 Sep; 33(9):921-6. PubMed ID: 12378518
[TBL] [Abstract][Full Text] [Related]
19. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization.
Burstein DE; Nagi C; Kohtz DS; Lee L; Wang B
Histopathology; 2006 May; 48(6):717-22. PubMed ID: 16681688
[TBL] [Abstract][Full Text] [Related]
20. Significance of p63 amplification and overexpression in lung cancer development and prognosis.
Massion PP; Taflan PM; Jamshedur Rahman SM; Yildiz P; Shyr Y; Edgerton ME; Westfall MD; Roberts JR; Pietenpol JA; Carbone DP; Gonzalez AL
Cancer Res; 2003 Nov; 63(21):7113-21. PubMed ID: 14612504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
